Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04677452
Other study ID # JWCAR129
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 2020
Est. completion date December 2024

Study information

Verified date December 2020
Source The First Affiliated Hospital of Soochow University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, Phase 1 dose exploration study to evaluate the safety and tolerability and to determine recommended Phase 2 dose(s) of JWCAR129, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 2024
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years old and above. 2. Signed the Informed Consent Form. 3. Diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Subjects must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen). Subjects must be refractory to the last anti-myeloma treatment regimen prior to entering the study. 1. Autologous hematopoietic stem cell transplantation. 2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination. Subjects must have undergone at least 2 consecutive cycles of treatment for each regimen unless progressive disease was the best response to the regimen. 3. Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy. Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible; the reason for not receiving treatment must be clearly documented in the case report form. 4. Subjects must have measurable disease. 5. Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required). 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 7. Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function Exclusion Criteria: 1. Subjects with known active or history of CNS involvement by malignancy 2. Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis 3. History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected. 4. Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R]) 5. Prior CAR T-cell or other genetically-modified T-cell therapy 6. Prior treatment with a BCMA-targeted agent 7. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis 8. Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JWCAR129 infusion. 9. History of any of the following cardiovascular conditions within 6 months of initial screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease 10. History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study 11. Allogeneic hematopoietic stem cell transplantation.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
JWCAR129
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).

Locations

Country Name City State
China First Affiliated Hospital, Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose-limiting toxicities (DLTs) Proportion of subjects with adverse events meeting DLT criteria 28 days
Primary Incidence and severity of adverse events Proportion of subjects with adverse events overall and by severity grade 2 years
Primary Incidence and severity of clinically significant laboratory abnormalities Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade 2 years
Secondary Cmax Maximum concentration (Cmax) of JWCAR129 in the blood 2 years
Secondary Tmax Time to maximum concentration (Tmax) of JWCAR129 in the blood 2 years
Secondary AUC Area under the concentration vs time curve (AUC) of JWCAR129 in the blood 2 years
Secondary Duration of persistence Duration of persistence of JWCAR129 CAR T cells in the blood 2 years
Secondary Overall response rate Proportion of subjects with a partial response (PR) or better by IMWG criteria 2 years
Secondary CR rate Proportion of subjects with a CR by IMWG criteria 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04994210 - Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL Phase 2
Terminated NCT05247957 - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia N/A
Completed NCT04621123 - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Phase 2
Recruiting NCT05140616 - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Phase 1/Phase 2
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed NCT03820596 - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Phase 1/Phase 2
Completed NCT02018250 - Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS) Phase 1
Recruiting NCT04446806 - Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Phase 4
Recruiting NCT05556889 - Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block N/A
Not yet recruiting NCT06244537 - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer N/A
Recruiting NCT03455972 - Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Phase 1/Phase 2
Completed NCT04785170 - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals N/A
Completed NCT01305044 - The HEALS Project - Health Education and Active Living for Surviving Seniors Phase 2
Active, not recruiting NCT04646590 - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Phase 3
Recruiting NCT05021276 - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Phase 4
Not yet recruiting NCT05008666 - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH Phase 2
Recruiting NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Phase 4
Active, not recruiting NCT04852068 - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) Phase 3